Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
Arnault
Jean Philippe
JP
Wechsler
Janine
J
Escudier
Bernard
B
Spatz
Alain
A
Tomasic
Gorana
G
Sibaud
Vincent
V
Aractingi
Selim
S
Grange
Jean-Didier
JD
Poirier-Colame
Vichnou
V
Malka
David
D
Soria
Jean-Charles
JC
Mateus
Christine
C
Robert
Caroline
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015603:Keratinocytes / Q000473:pathology*; D007636:Keratoacanthoma / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D000077157:Sorafenib; D013997:Time Factors
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib